CanSino Biologics Inc. (6185.HK)
- Previous Close
31.500 - Open
32.000 - Bid 32.900 x --
- Ask 32.950 x --
- Day's Range
32.000 - 33.600 - 52 Week Range
16.340 - 42.200 - Volume
1,608,200 - Avg. Volume
1,642,915 - Market Cap (intraday)
11.635B - Beta (5Y Monthly) 1.24
- PE Ratio (TTM)
-- - EPS (TTM)
-1.650 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 13, 2022
- 1y Target Est
39.53
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
www.cansinotech.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 6185.HK
View MorePerformance Overview: 6185.HK
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6185.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6185.HK
View MoreValuation Measures
Market Cap
11.08B
Enterprise Value
9.80B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.71
Price/Book (mrq)
1.47
Enterprise Value/Revenue
10.99
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-25.35%
Return on Assets (ttm)
-2.17%
Return on Equity (ttm)
-4.40%
Revenue (ttm)
869.22M
Net Income Avi to Common (ttm)
-220.33M
Diluted EPS (ttm)
-1.650
Balance Sheet and Cash Flow
Total Cash (mrq)
3.09B
Total Debt/Equity (mrq)
27.35%
Levered Free Cash Flow (ttm)
98.34M